The Best Dose of Esketamine for Day Surgery of Pediatric Circumcision Pediatric Circumcision
NCT ID: NCT04698434
Last Updated: 2022-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2021-01-15
2021-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Esketamine is an S-enantiomer of ketamine, which is newly marketed in China. Compared with ketamine, it has stronger effect on NMDA receptor, and its sedative effect is about twice as high. The occurrence frequency of respiratory depression and hypotension is lower than that of other anesthetics and analgesics, which can provide good analgesic and sedative effect for surgical anesthesia.
In clinical practice, ketamine combined with sevoflurane has been widely used in children's microsurgery, but there has been no report on Esketamine combined with sevoflurane anesthesia.
In order to find out the best combined dose, this paper compares the single administration of three different doses of esketamine combined with sevoflurane anesthesia in the circumcision of children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circumcision With a Novel Disposable Device in Chinese Children: a Hospital-based Randomized Controlled Trail
NCT01477593
Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery
NCT02848157
Evaluating the Analgesic Efficacy of Oxycodone Hydrochloride in Pediatric Laparoscopic Cryptorchidism Surgery
NCT06665048
Management of Post-circumcision Ischemia Using Hyperbaric Oxygen Therapy
NCT05152511
Caudal vs. Pudendal Block in Peds GU
NCT05708989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.5mg/kg esketamine group
0.5mg/kg esketamine group will be given a single intravenous 0.5mg/kg esketamine
Esketamine
each group was given a single intravenous dose of the corresponding esketamine.
.75mg/kg esketamine group
0.75mg/kg esketamine groupwill be given a single intravenous 0.75mg/kg esketamine
Esketamine
each group was given a single intravenous dose of the corresponding esketamine.
1.0mg/kg esketamine group
1.0mg/kg esketamine group will be given a single intravenous 1.5mg/kg esketamine
Esketamine
each group was given a single intravenous dose of the corresponding esketamine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Esketamine
each group was given a single intravenous dose of the corresponding esketamine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* asthma
* dysgnosia
* surdimutism
* hepatopathy or nephropathy
4 Years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yangzhou University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ma Hong
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sun Ji Hong, bachelor
Role: STUDY_CHAIR
Yangzhou University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Affiliated hospital of yangzhou university
Yangzhou, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Y015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.